MicroRNA expression profiling predicts clinical outcome of carboplatin/paclitaxel-based therapy in metastatic melanoma treated on the ECOG-ACRIN trial E2603

BACKGROUND: Carboplatin/paclitaxel (CP), with or without sorafenib, result in objective response rates of 18–20 % in unselected chemotherapy-naïve patients. Molecular predictors of survival and response to CP-based chemotherapy in metastatic melanoma (MM) are critical to improving the therapeutic in...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Clin Epigenetics
Päätekijät: Villaruz, Liza C., Huang, Grace, Romkes, Marjorie, Kirkwood, John M., Buch, Shama C., Nukui, Tomoko, Flaherty, Keith T., Lee, Sandra J., Wilson, Melissa A., Nathanson, Katherine L., Benos, Panayiotis V., Tawbi, Hussein A.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: BioMed Central 2015
Aiheet:
Research
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC4457092/
https://ncbi.nlm.nih.gov/pubmed/26052356
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13148-015-0092-2
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia